Publikationen

Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)

Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD - Duchow - 2024 - Annals of Neurology - Wiley Online Library

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.

Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
Effects of the COVID-19 Pandemic on Patients with NMO Spectrum Disorders and MOG-Antibody–Associated Diseases COPANMO(G)-Study (PDF)

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE NMO Study

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders

Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients

Pain, depression, and quality of life in adults with MOG-antibody-associated disease

 

« Therapie und Behandlungsempfehlung

letzte Aktualisierung: 20.08.2024

Aktuelles

Patient*innentag 2024

Datum: 02.10.2024 von 10-17 Uhr
Ort: Frankfurt am Main

Informationen zur Anmeldung:

Rare Disease Day 2024 - NEMOS Initiative für Betroffene
SAVE THE DATE

NEMOS Retreat 22.02.-23.02.24

Schloß Mickeln - Düsseldorf

NEMOS auf dem 96. DGN Kongress - Berlin

08.11. - 10.11.2023

zum Archiv